Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | February 06, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date February 06, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,682 |
Reported balance
After 2026-02-06 transaction · row 1
1 source rowRow 1 · 2026-02-06 · Purchase · Acquired 300 · Balance 65,682 |
| Common StockSEC Table I · non-derivative | Indirectas UTMA custodian for a minor child | 2,425 |
Reported balance
Holding disclosure · report date 2026-02-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,425 F1: These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Indirectheld in trust | 2,000 |
Reported balance
Holding disclosure · report date 2026-02-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,000 F2: These shares are held in a special needs trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.
F2: These shares are held in a special needs trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 9, 2026 21:25 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 300 | $2.70 | $810.00 |
DisclosureSEC source: 0001133416-26-000048 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,682 Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:49 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000034 · form4.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| December 23, 2025 Filed Dec 23, 2025 18:17 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 700 | $3.73 | $2,611.00 |
DisclosureSEC source: 0001133416-25-000078 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,382 Read SEC document |
| December 23, 2025 Filed Dec 23, 2025 16:28 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 700 | $3.73 | $2,611.00 |
DisclosureSEC source: 0001133416-25-000074 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,382 Read SEC document |
| July 21, 2025 Filed Jul 22, 2025 11:36 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 1,000 | $2.93 | $2,925.00 |
DisclosureSEC source: 0001133416-25-000035 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,682 Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-25-000008 · form4.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-01-23 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2025. Read SEC document |
| December 24, 2024 Filed Dec 26, 2024 13:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 13,469 | $0.82 | $11,044.58 |
DisclosureSEC source: 0001133416-24-000064 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,682 Read SEC document |
| October 23, 2024 Filed Oct 23, 2024 17:39 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 500 | $2.60 | $1,300.00 |
DisclosureSEC source: 0001133416-24-000060 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,213 Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 13:43 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 400 | $2.39 | $956.00 |
DisclosureSEC source: 0001133416-24-000048 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,713 Read SEC document |
| January 24, 2024 Filed Feb 7, 2024 21:46 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001133416-24-000014 · form4.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-01-24 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2024. Read SEC document |
| January 16, 2024 Filed Jan 16, 2024 16:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 500 | $1.79 | $892.90 |
DisclosureSEC source: 0001133416-24-000004 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,313 Read SEC document |
| January 16, 2024 Filed Jul 23, 2024 13:38 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 400 | $2.39 | $956.00 |
DisclosureSEC source: 0001133416-24-000046 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,713 Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 11:40 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 1,598 | $1.79 | $2,854.03 |
DisclosureSEC source: 0001133416-23-000065 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,813 Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 17:16 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 1,000 | $1.59 | $1,591.10 |
DisclosureSEC source: 0001133416-23-000043 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,215 Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:40 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-23-000020 · form4.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-01-26 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2023. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 12:44 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 1,300 | $1.11 | $1,443.00 |
DisclosureSEC source: 0001133416-23-000006 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,215 Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 21:49 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-22-000035 · form4.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-24 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2022. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013809 · doc4.xml · derivative · entry 2 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F3 · derivative.exercise_date: Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013809 · doc4.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: Such options vest 100% on March 31, 2022. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:05 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-20-001127 · doc4.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-01-09 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2020. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:42 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock Purchase Warrant (right to buy) · Derivative | 10,110 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000036 · edgar.xml · derivative · entry 4 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,110 Underlying: Common stock · 758 shares Expires 2026-05-31 F3 · shares: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F3 · balance_after: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:42 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 3,033 | $4.28 | $12,981.24 |
DisclosureSEC source: 0001179022-19-000036 · edgar.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,415 Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 22:20 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001179022-19-000017 · edgar.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The options vest 100% on January 16, 2020. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 11:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 2,000 | $6.10 | $12,199.80 |
DisclosureSEC source: 0001179022-18-000072 · edgar.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,382 Read SEC document |
| May 22, 2018 Filed May 29, 2018 20:30 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 46,875 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001179022-18-000043 · edgar.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common stock · 46,875 shares Expires 2028-05-22 F1 · derivative.exercise_date: The options vest 100% on May 22, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.